Miles Horton
Family · Dallas, TXNPI 1427446566
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,104 of the $71,684 with a category attached, or 72.7%. 58 manufacturers reported payments, led by AbbVie at 51.5% of the total. Reporting peaked in 2021 at $35,118 and has fallen 74.7% since, to $8,889 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 873 payments — averaging $82.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$37K
- Teva Pharmaceuticals USA, Inc.$7K
- Biohaven Pharmaceuticals, Inc.$7K
- Axsome Therapeutics, Inc.$4K
- Impel Pharmaceuticals LLC$3K
- Lundbeck LLC$2K
- plus $12K from 52 others
What the payments were for
- Consulting fees$2,1983%
- Speaking & faculty fees$52,10473%
- Travel & lodging$2,3823%
- Food & beverage$15,00021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$20,852
- UBRELVY$14,040
- NURTEC ODT$7,929
- AJOVY$5,575
- Symbravo$4,198
- Trudhesa$2,859
- VYEPTI$1,400
- ZEMBRACE SYMTOUCH$1,000
- ZAVZPRET$134
- EMGALITY$106
How this compares
$71,684 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 80 | $131,132 |
| Emgality PenGalcanezumab-Gnlm | 130 | $95,216 |
| Aimovig AutoinjectorErenumab-Aooe | 90 | $74,617 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 84 | $68,479 |
| QuliptaAtogepant | 56 | $66,144 |
| Nurtec OdtRimegepant Sulfate | 51 | $63,027 |
| Ajovy SyringeFremanezumab-Vfrm | 30 | $21,414 |
| Emgality SyringeGalcanezumab-Gnlm | 21 | $17,194 |
| Sumatriptan Succinate | 189 | $5,776 |
| Zolmitriptan | 17 | $3,452 |
| Gabapentin | 43 | $1,566 |
| Naratriptan Hcl | 34 | $1,315 |
| Topiramate | 61 | $1,242 |
| Eletriptan HbrEletriptan Hydrobromide | 20 | $1,122 |
| Memantine Hcl | 38 | $1,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $36,898 | $197,276136 claims |
| PfizerNurtec Odt | $473 | $63,02751 claims |
| Upsher-smith Laboratories LLCTopiramate | $545 | $1,24261 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Dallas
- David WeirDallas$959K
- Sie ThomasDallas$197K
- Marcia HarrisDallas$156K
- Natasha SimmonsDallas$38K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.